BioTek Offers Service Through Serlabo in France
News Jan 06, 2012
BioTek Instruments has announced a service partnership with Serlabo Technologies in France.
Serlabo Technologies was privately founded in 2002 and is ISO 9001:2000 certified.
In addition to the service agreement with BioTek, Serlabo offers high-quality products and services to private and public sector customers in France.
According to Philippe Vivier, BioTek France Director of Sales, "The service agreement with Serlabo in France will ensure that our BioTek customers continue to receive high quality instrument service with reduced downtime, and also benefit from a local, dedicated service technician."
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018
18th International Conference and Exhibition on Analytical & Bioanalytical Chromatographic Techniques
Nov 02 - Nov 03, 2017